Study links anesthesia choice to tolfenamic acid PK in cats
Bottom line
A new Animals study reports that the anesthetic protocol used during feline ovariohysterectomy may meaningfully alter the pharmacokinetics of subcutaneous tolfenamic acid, an NSAID given at 4 mg/kg before surgery. In 12 healthy cats, researchers compared xylazine–ketamine with propofol–isoflurane anesthesia and found different drug-exposure patterns between the two groups, adding early evidence that perioperative anesthesia choice can influence how tolfenamic acid is absorbed and handled in surgical patients. The authors describe this as the first detailed pharmacokinetic evaluation of subcutaneous tolfenamic acid in cats undergoing ovariohysterectomy under different anesthetic protocols. (mdpi.com)
Why it matters: For veterinary professionals, the paper is less about changing practice tomorrow and more about refining how perioperative analgesia is interpreted in cats. NSAID response in feline patients already requires caution because cats have limited approved postoperative NSAID options in the U.S., and adverse effects can involve the kidneys, liver, and gastrointestinal tract. If anesthesia changes perfusion, metabolism, or clearance enough to shift NSAID exposure, that could help explain some variability in analgesic effect or tolerability around routine surgeries such as spays. (fda.gov)
What to watch: The next step is whether follow-up studies connect these pharmacokinetic differences to real clinical outcomes, including pain control, rescue-analgesia needs, and renal safety in larger feline cohorts. (mdpi.com)
Key facts
- Study type
- Comparative pharmacokinetic study
- Journal
- Animals
- Species
- Cats
- Sample size
- 12 healthy cats
- Procedure
- Ovariohysterectomy
- Drug
- Subcutaneous tolfenamic acid
- Dose and timing
- 4 mg/kg, 30 minutes before surgery
- Anesthetic protocols
- Xylazine-ketamine vs propofol-isoflurane
- Main finding
- The anesthetic protocol altered tolfenamic acid pharmacokinetics and drug-exposure patterns
Anesthesia choice may do more than shape monitoring parameters in the OR. A newly published study in Animals suggests it can also change the pharmacokinetic profile of subcutaneous tolfenamic acid in cats undergoing ovariohysterectomy, potentially affecting how this NSAID performs in the perioperative setting. In the trial, 12 healthy cats were randomized to xylazine–ketamine or propofol–isoflurane anesthesia, then given tolfenamic acid at 4 mg/kg subcutaneously 30 minutes before surgery. (mdpi.com)
That question matters because feline pain management already operates within a narrow margin for safety and label flexibility. In the U.S., FDA says only meloxicam, as a single preoperative subcutaneous dose, and robenacoxib, for up to three days, are approved NSAIDs for short-term postoperative use in cats, and no NSAIDs are approved for long-term feline use. FDA also notes that NSAIDs can cause serious gastrointestinal, renal, and hepatic adverse effects, especially in higher-risk patients. (fda.gov)
Against that backdrop, tolfenamic acid occupies an interesting place in feline medicine. It is used in some markets for cats, and older feline pain literature has described it as a licensed anti-inflammatory option in the UK and a few other countries. Prior studies have also compared its postoperative analgesic efficacy with other feline analgesics, including robenacoxib and meloxicam, in surgical settings. The new paper adds a missing layer: how the anesthetic plan itself may change tolfenamic acid exposure during a common procedure. (pmc.ncbi.nlm.nih.gov)
According to the study summary, the authors enrolled clinically healthy cats presented for scheduled ovariohysterectomy and selected animals with normal physical examination, hematology, serum biochemistry, vaginal cytology, and abdominal ultrasonography findings. Their rationale was straightforward: anesthetic drugs can alter body perfusion, hepatic and renal function, and plasma protein binding, all of which can shift drug disposition. The paper specifically notes that xylazine–ketamine is associated with greater hemodynamic and metabolic changes than isoflurane-based anesthesia, which may help explain the between-group pharmacokinetic differences they observed. (mdpi.com)
Independent expert reaction specific to this paper was limited at the time of writing, but the broader literature supports the study’s premise. Feline anesthesia guidance notes that alpha-adrenergic agonists can reduce cardiac output and slow the onset of subsequent drugs, while pain-management guidance in cats has long emphasized that species-specific pharmacokinetics are central to safe NSAID dosing. In other words, the idea that anesthesia protocol could change NSAID exposure is pharmacologically plausible, even if this was a small exploratory study. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinarians, this is a reminder that perioperative analgesia is a systems question, not just a dose-selection question. If two standard anesthetic approaches produce different NSAID exposure profiles, clinicians may eventually need to think more carefully about how anesthetic choice, fluid status, cardiovascular effects, and analgesic timing interact, especially in cats with marginal renal perfusion or other comorbidities. The study does not establish that one protocol is clinically superior, and it does not show outcome differences such as better pain scores or fewer adverse events. But it does suggest that “same drug, same dose” may not mean “same exposure” in anesthetized feline patients. (mdpi.com)
There are also clear limitations. The study included only 12 cats, focused on healthy spay patients, and appears to be primarily pharmacokinetic rather than outcomes-based. That means the findings are best read as hypothesis-generating, not practice-changing. For U.S. clinicians in particular, tolfenamic acid’s relevance may be more conceptual than immediate, since feline NSAID choices remain tightly constrained by approved labeling and extra-label risk considerations. (mdpi.com)
What to watch: Watch for larger studies that pair pharmacokinetic findings with pain scores, rescue-analgesia rates, renal biomarkers, and recovery quality, as well as any work testing whether anesthetic-dependent exposure differences extend to other feline NSAIDs used around surgery. (mdpi.com)